| Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. | |
| | |
MedLine Citation:
|
PMID: 23143207 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: Liver metastases in patients with cancer are associated with poor survival. We hypothesized that hepatic arterial infusion (HAI) of oxaliplatin combination therapy would have antitumor activity in these patients. PATIENTS AND METHODS: Patients with advanced cancer and predominant liver metastases were treated on a phase I study of HAI oxaliplatin in combination with systemic bevacizumab, with or without HAI or systemic fluorouracil and/or leucovorin and/or cetuximab. Patients were divided into two treatment arms according to KRAS mutational status and physician choice. A "3 + 3" design was used. RESULTS: Among 76 patients (median age 61 years; 34 women; median number of prior therapies 4), the most common cancer was colorectal (CRC) (n = 58). Overall, the only dose-limiting toxicity was Grade 3 diarrhea (n = 2). The most common treatment-related toxicities were hypertension (n = 40), nausea (n = 29), fatigue (n = 28), and transaminitis (n = 26). Of 76 patients, one (1 %) had a complete response (CR), 12 (16 %) had a partial response (PR), and 12 (16 %) had SD for ≥6 months (total CR/PR/SD ≥6 months 25/76 = 33 %). In CRC (n = 58), total CR/PR/SD ≥6 months was 31 % (n = 18). Both patients with pancreatic neuroendocrine tumors achieved a PR (24+ months) and a CR (6+ months). Time to treatment failure (TTF) on the current regimen was 3.5 versus 2.8 months on patients' prior systemic treatment (p = 0.37). CONCLUSIONS: HAI oxaliplatin combination therapy with 5-fluorouracil, leucovorin, bevacizumab, and/or cetuximab was well tolerated and had antitumor activity in selected heavily pretreated patients with predominant liver disease. |
| | |
Authors:
|
Apostolia M Tsimberidou; Mark B Leick; Joann Lim; Siqing Fu; Jennifer Wheler; Sarina A Piha-Paul; David Hong; Gerald S Falchook; Aung Naing; Ishwaria M Subbiah; Adoneca Fortier; Rony Avritscher; Razelle Kurzrock |
Related Documents
:
|
9267247 - Theoretical and empirical arguments in relation to elective lymph node dissection for m... 2168277 - Metastatic malignant melanoma of upper gastrointestinal tract. 3897817 - Adjuvant therapy of cutaneous malignant melanoma: a critical review. 1118487 - Intralesional bcg, intravenous immune lymphocytes, and immunization with neuraminidase-... 9476047 - Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cance... 16618907 - Intensification regimen for advanced-stage resectable hypopharyngeal carcinoma. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-11-11 |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: - ISSN: 1432-0843 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-12 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA, atsimber@mdanderson.org. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Large aneurysm of left coronary sinus of Valsalva presenting with effort-related ventricular fibrill...
Next Document: Synthesis and characterization of some new Schiff base complexes of group 13 elements, ab initio stu...